KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer
作者： Peter Camaj , Stefano Primo , Yan Wang , Volker Heinemann , Yue Zhao
DOI: 10.2217/FON.15.97
关键词: In vivo 、 Apoptosis 、 Cancer research 、 Colorectal cancer 、 Nod 、 Medicine 、 Mutant 、 Exon 、 Regorafenib 、 KRAS
摘要: ABSTRACT Aim: To investigate the impact of KRAS mutation variants on activity regorafenib in SW48 colorectal cancer cells. Materials & methods: Activity was evaluated isogenic wild-type (WT) and mutant Subcutaneous xenografts (KRAS WT G12C variants) NOD/SCID mice were analyzed to elucidate effect treatment vivo. Results: Compared with cells, all seemed associated some degree resistance regorafenib-treatment vitro. In vivo, activation apoptosis (TUNEL) reduction proliferation (Ki67) after more pronounced tumors as compared variants. Conclusion: exon 2 mutations gene may influence antitumor effects regorafenib.
futuremedicine.com
sci-hub.se 参考文章(21)
Roberta Schmieder, Jens Hoffmann, Michael Becker, Ajay Bhargava, Tina Müller, Nicole Kahmann, Peter Ellinghaus, Robert Adams, André Rosenthal, Karl‐Heinz Thierauch, Arne Scholz, Scott M. Wilhelm, Dieter Zopf, Regorafenib (BAY 73‐4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer International Journal of Cancer. ,vol. 135, pp. 1487- 1496 ,(2014) , 10.1002/IJC.28669
Scott M. Wilhelm, Jacques Dumas, Lila Adnane, Mark Lynch, Christopher A. Carter, Gunnar Schütz, Karl-Heinz Thierauch, Dieter Zopf, Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity International Journal of Cancer. ,vol. 129, pp. 245- 255 ,(2011) , 10.1002/IJC.25864
Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Dongsheng Tu, Salvatore Siena, Simona Lamba, Sabrina Arena, Milo Frattini, Hubert Piessevaux, Eric Van Cutsem, Chris J. O’Callaghan, Shirin Khambata-Ford, John R. Zalcberg, John Simes, Christos S. Karapetis, Alberto Bardelli, Sabine Tejpar, Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab JAMA. ,vol. 304, pp. 1812- 1820 ,(2010) , 10.1001/JAMA.2010.1535
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Jörg Hielscher, Michael Scholz, Sebastian Müller, Hartmut Link, Norbert Niederle, Andreas Rost, Heinz-Gert Höffkes, Markus Moehler, Reinhard U Lindig, Dominik P Modest, Lisa Rossius, Thomas Kirchner, Andreas Jung, Sebastian Stintzing, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncology. ,vol. 15, pp. 1065- 1075 ,(2014) , 10.1016/S1470-2045(14)70330-4
D Strumberg, M E Scheulen, B Schultheis, H Richly, A Frost, M Büchert, O Christensen, M Jeffers, R Heinig, O Boix, K Mross, Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. British Journal of Cancer. ,vol. 106, pp. 1722- 1727 ,(2012) , 10.1038/BJC.2012.153
Iram F Khan, Roli K Hirata, David W Russell, AAV-mediated gene targeting methods for human cells. Nature Protocols. ,vol. 6, pp. 482- 501 ,(2011) , 10.1038/NPROT.2011.301
Jens Neumann, Evelyn Zeindl-Eberhart, Thomas Kirchner, Andreas Jung, Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathology Research and Practice. ,vol. 205, pp. 858- 862 ,(2009) , 10.1016/J.PRP.2009.07.010
Isabelle Messner, Giuseppe Cadeddu, Wolfgang Huckenbeck, Helen J. Knowles, Helmut E. Gabbert, Stephan E. Baldus, Karl-Ludwig Schaefer, KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines Journal of Cancer Research and Clinical Oncology. ,vol. 139, pp. 201- 209 ,(2013) , 10.1007/S00432-012-1319-7
D. P. Modest, P. Camaj, V. Heinemann, B. Schwarz, A. Jung, R. P. Laubender, S. Gamba, C. Haertl, S. Stintzing, S. Primo, C. J. Bruns, KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer. Journal of Cancer Research and Clinical Oncology. ,vol. 139, pp. 953- 961 ,(2013) , 10.1007/S00432-013-1401-9
Jean-Yves Douillard, Kelly S Oliner, Salvatore Siena, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, Gyorgy Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocákova, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean Luc Canon, Mark Rother, Richard Williams, Alan Rong, Jeffrey Wiezorek, Roger Sidhu, Scott D Patterson, None, Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer The New England Journal of Medicine. ,vol. 369, pp. 1023- 1034 ,(2013) , 10.1056/NEJMOA1305275